Verified Supplement Data Primary-sourced

Probiotics for Women: Which Strain for Which Problem

By Erin Rose · Published · Reviewed against primary sources · Methodology · About Us

Informational summary of published trials and guidelines, not medical advice. Active BV, a yeast infection or a UTI needs diagnosis and treatment; a probiotic is at most an add-on. If you are pregnant, immunocompromised or critically ill, ask your clinician before taking any live organism.

Quick answer

Of the 77 “women’s probiotic” labels we read, 14.3% name the two strains with randomized vaginal-health trials, which the bacterial vaginosis trial gave at 1 billion CFU of each strain, twice daily. A “women’s probiotic” is a marketing category, not a clinical one. Probiotic effects belong to individual strains, so the question is which strain for which problem. For the vaginal tract, the strains with randomized trials are L. rhamnosus GR-1 and L. reuteri RC-14, taken by mouth. For antibiotic-associated diarrhea, the strains are L. rhamnosus GG or S. boulardii. For IBS, one strain has a large trial in women and the guidelines still say no to the class. For recurrent UTI and pregnancy, none has earned a recommendation.

The shelf does not carry the strains the trials used. We read 896 probiotic labels filed with the NIH, 77 of them marketed to women: 14.3% of women’s labels name GR-1 or RC-14, 2.6% name L. crispatus, the organism that dominates a healthy vagina, and 93.5% put their strains inside a proprietary blend that hides the amount of each. See the census →

BV cure at day 30 · antibiotic + GR-1/RC-1488%vs 40% on antibiotic alone (Anukam 2006)
Recurrent UTI · probiotic vs placeboRR 0.82not significant (Cochrane 2015)
Women’s labels naming GR-1 / RC-14 14.3% our census of 77 women’s labels

Know your strain already? See the best probiotic guide, ranked by what each is evidenced for →

On this page
  1. Strain by problem
  2. Vaginal health & BV
  3. Recurrent UTI
  4. IBS & gut
  5. Pregnancy & antibiotics
  6. What women’s labels contain
  7. FAQ

The strain for each problem, with the dose the trials used

Probiotic evidence is strain-specific and disease-specific: a systematic review of 228 trials found that efficacy tracked the specific strain and the specific condition, and that strains of the same species did not share results (McFarland 2018, PMID 29868585). So the table starts from the problem. Doses are the ones the cited trial used; the strain code after the species name is the part of a label that maps to a trial.

Probiotics for women by problem: the strain with randomized evidence, the dose and route in the trial, what it found, and our verdict.
ProblemStrain with evidenceDose in the trialWhat the trial foundVerdict
Restoring vaginal floraL. rhamnosus GR-1 + L. reuteri RC-14, oralOver 108 organisms/day was the dose needed; L. rhamnosus GG had no effect (Reid 2001)64 healthy women, 60 days: flora normalized in 37% vs 13% on placebo (Reid 2003)Modest, real
Bacterial vaginosis, with antibioticGR-1 + RC-14, oral, alongside metronidazole1 billion CFU of each strain, twice daily, 30 days125 women: cured at day 30 in 88% vs 40% (Anukam 2006); Cochrane: promising, insufficient (Senok 2009)Add-on only
BV recurrence after treatmentL. crispatus CTV-05, intravaginal11 weeks after metronidazole gel228 women: recurrence by week 12 in 30% vs 45% (Cohen 2020)Not sold as a supplement
Yeast infectionVarious, as add-on to antifungalsTrial-specific10 trials, 1,656 women: short-term cure up 14%, no long-term difference; low quality (Xie 2017)Weak
Recurrent UTINone established orallyGR-1 + RC-14 at 109 CFU twice daily for 12 months (Beerepoot 2012)Pooled: RR 0.82, not significant (Schwenger 2015); intravaginal L. crispatus 15% vs 27% recurrence, n=100 (Stapleton 2011)Not established
IBSB. infantis 35624108 CFU/day, 4 weeks; 1010 did no better362 women with IBS: pain and bloating improved vs placebo (Whorwell 2006); guidelines advise against the class (Lacy 2021)One strain, four-week trial
Antibiotic-associated diarrheaL. rhamnosus GG or S. boulardii5 billion CFU/day or more worked better than less (Guo 2019)63 trials, 11,811 people: RR 0.58 (Hempel 2012); children 8% vs 19% (Guo 2019)Strongest use
PregnancyNo strain proven for a pregnancy outcomen/aNo malformation signal (Dugoua 2009); pre-eclampsia higher in diabetes-prevention trials, RR 1.85 (Davidson 2021)Only for a specific reason

Route matters as much as strain. Every intravaginal result above is an investigational product that is not on sale; supplements are oral, and only GR-1 and RC-14 have shown that the oral route reaches the vaginal tract.

Vaginal health: two strains have the trials, one organism dominates the healthy state

A healthy vagina is usually dominated by a single Lactobacillus species. When 396 asymptomatic women were sequenced, their vaginal communities fell into five groups: four dominated by L. crispatus, L. iners, L. gasseri or L. jensenii, and a fifth with fewer lactobacilli and more anaerobes, the pattern associated with bacterial vaginosis (Ravel 2011, PMID 20534435). None of those four is the L. acidophilus or L. plantarum that fills most women’s-probiotic labels.

The oral evidence belongs to two strains. In a randomized trial, 64 healthy women took capsules of L. rhamnosus GR-1 and L. reuteri RC-14 (then called L. fermentum RC-14) or placebo daily for 60 days: the flora shifted from an asymptomatic BV pattern to a normal lactobacilli pattern in 37% of the probiotic group against 13% on placebo, with less yeast and fewer coliforms on culture and no adverse effects (Reid 2003, PMID 12628548). The dose-finding study that preceded it is the one to remember when reading labels: more than 108 viable organisms a day was the dose required, and L. rhamnosus GG, the most-studied probiotic strain in the world and the one in Culturelle, failed to have any effect on vaginal flora (Reid 2001, PMID 11750220).

For diagnosed bacterial vaginosis, the strains are an add-on to the antibiotic, not a substitute. In 125 premenopausal women with BV treated with oral metronidazole for a week, those randomized to add GR-1 and RC-14 at 1 billion CFU each twice daily for 30 days were cured at day 30 in 88% of cases against 40% on antibiotic plus placebo, among the 106 women who returned for the day-30 visit (Anukam 2006, PMID 16697231). The Cochrane review that weighed this and three other trials called the metronidazole-plus-probiotic regimen promising and the evidence insufficient for or against recommending probiotics to treat BV (Senok 2009, PMID 19821358). That is the honest reading: a strong single trial, no confirmation at scale.

The best recurrence result uses the dominant organism directly. Lactin-V, an intravaginal L. crispatus CTV-05 product, given for 11 weeks after metronidazole gel to 228 women, cut BV recurrence by week 12 from 45% to 30% (Cohen 2020, PMID 32402161). It is an investigational product, not a capsule you can buy, and the organism it uses is the one almost no label carries. For yeast infections the picture is weaker. The Cochrane review of 10 trials in 1,656 non-pregnant women found probiotics added to antifungals raised short-term clinical cure (RR 1.14) and lowered relapse at one month (RR 0.34) on low- and very-low-quality evidence, with no difference in long-term cure (Xie 2017, PMID 29168557). The vaginal-health product page covers the GR-1/RC-14 products themselves.

Recurrent UTI: the probiotic evidence is null, the cranberry evidence is not

The Cochrane review of probiotics for preventing urinary tract infection included nine trials and 735 people and found no significant reduction in recurrent symptomatic UTI against placebo (six trials, 352 participants, RR 0.82, 95% CI 0.60 to 1.12), with a high risk of bias throughout (Schwenger 2015, PMID 26695595). A phase 2 trial gave 100 premenopausal women with recurrent UTI an intravaginal L. crispatus suppository or placebo after antibiotic treatment: recurrence was 15% against 27%, a relative risk of 0.5 whose confidence interval crossed 1, and the benefit tracked with how well the strain colonized (Stapleton 2011, PMID 21498386). And 252 postmenopausal women with recurrent UTI were randomized to a year of daily trimethoprim-sulfamethoxazole or oral GR-1/RC-14 at 109 CFU twice daily: the probiotic group averaged 3.3 UTIs a year against 2.9, which missed the noninferiority margin, but their E. coli did not become resistant, while in the antibiotic group resistance climbed from roughly 20–40% to 80–95% within a month (Beerepoot 2012, PMID 22782199).

So an oral probiotic is not an established UTI preventive, nor a substitute for prophylaxis a clinician has prescribed. The ingredient on a women’s label that does have evidence for this problem is cranberry. The 2023 Cochrane update found cranberry products probably reduce symptomatic, culture-verified UTIs in women with recurrent infections (eight trials, 1,555 participants, RR 0.74, 95% CI 0.55 to 0.99), with little or no benefit in pregnant women or institutionalized elderly people (Williams 2023, PMID 37947276). That argues for a cranberry product at a trial-like dose, not a probiotic capsule with a token amount of cranberry in it.

IBS and the gut: one strain has a trial in women, the guidelines still say no to the class

The largest single-strain IBS trial was run in women. 362 primary-care patients took placebo or encapsulated Bifidobacterium infantis 35624 at 106, 108 or 1010 CFU a day for four weeks; the 108 dose beat placebo on abdominal pain, bloating and gas, the 106 dose did nothing, and the 1010 dose was no better (Whorwell 2006, PMID 16863564). That is the clearest demonstration that more CFU is not more effect.

Step back to the whole evidence base and the picture blurs. A meta-analysis of 53 trials in 5,545 IBS patients found that particular strains appeared to help global symptoms and pain, but which ones remained, in the authors’ words, for the most part unclear (Ford 2018, PMID 30294792). The American College of Gastroenterology guideline that followed suggests against probiotics for global IBS symptoms (Lacy 2021, PMID 33315591), and the American Gastroenterological Association guideline recommends probiotics for IBS only within a clinical trial, reserving its positive suggestions for narrow settings such as preventing C. difficile infection during antibiotics (Su 2020, PMID 32531291). The reasonable path: pick a strain with its own trial, give it four weeks at the trial dose, and stop if nothing changes. The IBS page ranks the buyable options; the 35624 product itself is currently unavailable, and B. coagulans BC30 is the cheapest strain there with IBS-D trial data.

Nothing in the IBS evidence is specific to women beyond the trial population. A gut probiotic does not need to say “women’s” on the box.

Pregnancy and antibiotics: safe for most, best-supported during a course

Pregnancy first. A meta-analysis of 11 randomized trials of Lactobacillus and Bifidobacterium in 1,505 pregnant women found no effect on cesarean section, birth weight or gestational age and no malformations; it found no pregnancy trials of Saccharomyces at all, so the safety of S. boulardii in pregnancy is unknown (Dugoua 2009, PMID 19646321). A 2021 review reached the same conclusion for pregnancy and lactation, with one trial reporting more vaginal discharge and changes in stool consistency on L. rhamnosus plus L. reuteri and nothing serious (Sheyholislami 2021, PMID 34371892). Across 622 studies in the wider safety literature, randomized trials showed no increase in adverse events with short-term use; the case reports of fungemia and bacteremia cluster in people whose health was already compromised (Hempel 2011, PMID 23126627).

Safe is not the same as useful. The Cochrane review of probiotics to prevent gestational diabetes (seven trials, 1,647 women; six trials and 1,440 women contributed to the diabetes estimate) found it uncertain whether they affect the risk at all (RR 0.80, 95% CI 0.54 to 1.20, low certainty), and found more pre-eclampsia in the probiotic groups (RR 1.85, 95% CI 1.04 to 3.29, four trials, 955 women, high certainty) (Davidson 2021, PMID 33870484). A pregnancy is not a reason to take a probiotic; a specific problem, discussed with the person managing it, might be.

Antibiotics are the opposite case: the one use where a probiotic is strongly supported, and BV and UTI are both treated with them. In a meta-analysis of 63 randomized trials with 11,811 participants, probiotics reduced antibiotic-associated diarrhea by 42% (RR 0.58, 95% CI 0.50 to 0.68), with a number needed to treat of 13 (Hempel 2012, PMID 22570464). The pediatric Cochrane review of 33 trials put the incidence at 8% with a probiotic against 19% without, and found that 5 billion CFU a day or more worked better than lower doses (Guo 2019, PMID 31039287). L. rhamnosus GG and S. boulardii are the best-tested; S. boulardii is a yeast, so the antibiotic cannot kill it, while a bacterial strain goes a couple of hours away from the antibiotic dose. Start with the first antibiotic dose and continue for about a week after the course; if the course is metronidazole for BV, GR-1/RC-14 is the pair that was tested alongside it. The antibiotic-diarrhea page has the product comparison.

We read 896 probiotic labels: what a “women’s probiotic” actually contains

Original research Every on-market probiotic label filed with the NIH Dietary Supplement Label Database that we could retrieve (900 read, 896 analyzed), split into 77 women-marketed labels (the product name says women, her, feminine or vaginal) and 819 general labels, with the organisms named in the Supplement Facts rows tallied by label. This census counts strains named, not dose: DSLD does not carry CFU as a machine-readable quantity, so no figure here says how much of any strain a capsule holds.

14.3% of women’s labels name L. rhamnosus GR-1 or L. reuteri RC-14, the two strains with the vaginal trials; about one label in 7. 2.6% name L. crispatus, the organism that dominates the healthy vaginal state and the one in the BV-recurrence and UTI trials, against 0.5% of general labels. And 93.5% of women’s labels put their strains inside a proprietary-blend row: a total for the blend, nothing for any strain in it. The typical general label names 5 species. Only 8.8% of general labels carry a CFU figure the database can read as a quantity.

Share of labels naming the strains the vaginal trials used
0% 10% 20% 30% 40% Women's: GR-1 / RC-14 14.3% Women's: L. crispatus 2.6% General: L. crispatus 0.5%
14.3% of women's labels name GR-1 or RC-14 and 2.6% name L. crispatus, against 0.5% of general labels; the proprietary-blend share (93.5% of women's labels) is a different measure and is stated in the text. Source: Our census of 77 women-marketed and 819 general DSLD probiotic labels, 2026-09-16; strains named, not CFU.
Share of labels naming the strains the vaginal trials used
ItemValue (%)
Women's: GR-1 / RC-1414.3%
Women's: L. crispatus2.6%
General: L. crispatus0.5%

Put the two halves of this page together. The trials that justify a probiotic for vaginal health used two named strains at a stated dose; the product built for that shopper names them one time in 7, and in 93.5% of cases would not state the dose even if it did. What fills the label instead is a longer list of species with gut trials or none, plus cranberry or D-mannose for the UTI reader. The share of women’s labels adding cranberry or D-mannose did not hold in both halves of our sample, and neither did the women’s readable-CFU share or the median species count on women’s labels, so none of those three numbers is printed. What survives is enough: the women’s shelf is a general probiotic with a different name.

Method: 900 labels retrieved from the NIH Dietary Supplement Label Database (DSLD) v9 on 2026-09-16; 896 were analyzable, of which 77 carry women, her, feminine or vaginal in the product name and 819 do not. Organisms were read from the Supplement Facts rows, including rows inside a proprietary blend; a label counts as naming a strain if the strain designation appears anywhere in its rows. CFU was counted only when DSLD records it as a structured quantity, which is rare, so this census reports strains named and makes no claim about dose. Percentages are against the labels in each group. Every figure was recomputed in both halves of the read (split by DSLD id parity within each group): 6 of 9 findings held within tolerance; the 3 that did not (women’s structured-CFU share, women’s cranberry or D-mannose share, and the median species count on women’s labels) are named above but not printed as numbers. The figures are published as open data (CC BY 4.0). What it cannot tell you: how many CFU of any strain a capsule holds, whether the strain named is viable at expiry, which products sell most, or anything about products not filed with the NIH.

The product links below go to Amazon and we may earn a commission if you buy. It never changes which product we pick or what we say about it. How we choose.

For the vaginal tract: the product that carries GR-1 and RC-14 by name is Jarrow Fem-Dophilus, and it currently shows no offer on Amazon (checked 2026-09-08). No other product we track documents those strains, so we will not point you at a substitute for a strain-specific claim. If you find it elsewhere, the trials used more than 108 organisms a day (Reid 2001) and up to 109 of each strain twice daily alongside metronidazole (Anukam 2006).

For an antibiotic course or a general gut strain: Culturelle Daily Probiotic (10B CFU, 30ct) $0.59/day delivers 10 billion CFU of L. rhamnosus GG, the strain in the antibiotic-diarrhea trials, above the 5 billion CFU threshold. It is not a vaginal-health product: GG failed to shift vaginal flora in the dose-finding trial above.

If the antibiotic would kill a bacterial strain: Florastor Daily Probiotic (250mg S. boulardii, 30ct) $0.80/day is S. boulardii, a yeast, so it can be taken at the same time as the antibiotic. No pregnancy safety data exist for it.

For IBS-type symptoms on a budget: Schiff Digestive Advantage Daily Probiotic (2B CFU BC30, 60ct) $0.29/day is B. coagulans BC30, a shelf-stable spore strain with its own IBS-D trial data; the IBS page explains why it stands in for the unavailable 35624 product.

Frequently asked questions

What is the best probiotic for women?

There is no single one, because probiotic effects belong to strains, not to a "for women" label. For vaginal flora and bacterial vaginosis the strains with randomized trials are Lactobacillus rhamnosus GR-1 and L. reuteri RC-14, taken by mouth. For diarrhea during antibiotics: L. rhamnosus GG or Saccharomyces boulardii. For IBS: Bifidobacterium infantis 35624, though guidelines do not recommend the class. Pick the problem first, then the strain tested for it; in our census only 14.3% of 77 women's labels named GR-1 or RC-14.

Do women need a different probiotic than men?

Only when the problem is different. Gut strains work the same way in either sex. The one sex-specific use is the vaginal tract, where a small number of strains have been shown to reach it after oral dosing. If your goal is gut-related, a "women's" label adds nothing; if it is vaginal, look for GR-1 and RC-14 by name.

Which probiotic strain is best for bacterial vaginosis?

L. rhamnosus GR-1 with L. reuteri RC-14 has the oral trials: in a trial of 125 women with BV taking metronidazole, adding the two strains for 30 days raised the day-30 cure rate from 40% to 88% among the 106 who completed follow-up (Anukam 2006). A 2009 Cochrane review called that regimen promising but the evidence insufficient. Probiotics are an add-on to treatment, not a replacement. For recurrence, the strongest trial used an intravaginal L. crispatus product not sold as a supplement.

Can a probiotic prevent urinary tract infections?

Not reliably. The Cochrane review of probiotics for UTI prevention found no significant reduction in recurrent UTI versus placebo (risk ratio 0.82, high risk of bias). An intravaginal L. crispatus suppository halved recurrence in a 100-woman phase 2 trial, but it is not on shelves, and oral GR-1/RC-14 did not match a daily antibiotic in postmenopausal women. Cranberry has better evidence for recurrent UTI in women than probiotics do.

Is it safe to take a probiotic during pregnancy?

The safety reviews are reassuring for Lactobacillus and Bifidobacterium: a meta-analysis of 11 randomized trials found no effect on cesarean rate, birth weight or gestational age and no malformations. Two cautions. Saccharomyces boulardii has no pregnancy trials. And the Cochrane review of probiotics to prevent gestational diabetes found no clear effect on diabetes but more pre-eclampsia in the probiotic groups. Take one for a specific reason agreed with your clinician, not as a general pregnancy supplement.

Should I take a probiotic with antibiotics for BV or a UTI?

This is the best-supported use of any probiotic. Across 63 randomized trials in adults and children, probiotics cut antibiotic-associated diarrhea by about 42% (Hempel 2012); in the pediatric Cochrane review, doses of 5 billion CFU a day or more worked better than lower doses (Guo 2019). L. rhamnosus GG and S. boulardii are the best-tested; S. boulardii is a yeast, so the antibiotic cannot kill it. Start with the first antibiotic dose, take bacterial strains a couple of hours away from it, and continue for a week after the course.

Why does a women's probiotic list cranberry or D-mannose?

Because the label is built around the UTI shopper. Cranberry has its own evidence: the 2023 Cochrane review found cranberry products probably reduce symptomatic UTIs in women with recurrent infections (risk ratio 0.74). That is a cranberry result, not a probiotic one, and the cranberry dose in a combined capsule is rarely the trial dose. The share of women's labels adding cranberry or D-mannose did not hold in both halves of our sample, so we print no number for it.

Related guides

Sources

  1. Reid G, et al. "Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women." FEMS Immunol Med Microbiol. 2003. PMID: 12628548
  2. Reid G, et al. "Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora." FEMS Immunol Med Microbiol. 2001. PMID: 11750220
  3. Anukam K, et al. "Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial." Microbes Infect. 2006. PMID: 16697231
  4. Senok AC, et al. "Probiotics for the treatment of bacterial vaginosis." Cochrane Database Syst Rev. 2009. PMID: 19821358
  5. Cohen CR, et al. "Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis." N Engl J Med. 2020. PMID: 32402161
  6. Ravel J, et al. "Vaginal microbiome of reproductive-age women." Proc Natl Acad Sci U S A. 2011. PMID: 20534435
  7. Xie HY, et al. "Probiotics for vulvovaginal candidiasis in non-pregnant women." Cochrane Database Syst Rev. 2017. PMID: 29168557
  8. Schwenger EM, et al. "Probiotics for preventing urinary tract infections in adults and children." Cochrane Database Syst Rev. 2015. PMID: 26695595
  9. Stapleton AE, et al. "Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection." Clin Infect Dis. 2011. PMID: 21498386
  10. Beerepoot MA, et al. "Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women." Arch Intern Med. 2012. PMID: 22782199
  11. Williams G, et al. "Cranberries for preventing urinary tract infections." Cochrane Database Syst Rev. 2023. PMID: 37947276
  12. Whorwell PJ, et al. "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome." Am J Gastroenterol. 2006. PMID: 16863564
  13. Ford AC, et al. "Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome." Aliment Pharmacol Ther. 2018. PMID: 30294792
  14. Lacy BE, et al. "ACG Clinical Guideline: Management of Irritable Bowel Syndrome." Am J Gastroenterol. 2021. PMID: 33315591
  15. Su GL, et al. "AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders." Gastroenterology. 2020. PMID: 32531291
  16. Guo Q, et al. "Probiotics for the prevention of pediatric antibiotic-associated diarrhea." Cochrane Database Syst Rev. 2019. PMID: 31039287
  17. Hempel S, et al. "Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis." JAMA. 2012. PMID: 22570464
  18. Dugoua JJ, et al. "Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp." J Obstet Gynaecol Can. 2009. PMID: 19646321
  19. Sheyholislami H, Connor KL. "Are Probiotics and Prebiotics Safe for Use during Pregnancy and Lactation? A Systematic Review and Meta-Analysis." Nutrients. 2021. PMID: 34371892
  20. Davidson SJ, et al. "Probiotics for preventing gestational diabetes." Cochrane Database Syst Rev. 2021. PMID: 33870484
  21. Hempel S, et al. "Safety of probiotics used to reduce risk and prevent or treat disease." Evid Rep Technol Assess. 2011. PMID: 23126627
  22. McFarland LV, et al. "Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis." Front Med (Lausanne). 2018. PMID: 29868585
  23. NIH Office of Dietary Supplements. Dietary Supplement Label Database. dsld.od.nih.gov (probiotic labels retrieved 2026-09-16).